In the BioHarmony Drug Report Database
Vibegron
Gemtesa (vibegron) is a small molecule pharmaceutical. Vibegron was first approved as Gemtesa on 2020-12-23. It is used to treat overactive urinary bladder in the USA. The pharmaceutical is active against beta-3 adrenergic receptor. Gemtesa’s patents are valid until 2030-12-01 (FDA).
Trade Name
|
Gemtesa |
|---|---|
Common Name
|
vibegron |
ChEMBL ID
|
CHEMBL2107826 |
Indication
|
overactive urinary bladder |
Drug Class
|
Beta 3 adrenoreceptor agonist |
Image (chem structure or protein)